Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of graft versus host disease prophylaxis with post transplant cyclophosphamide on the prognostic value of HCT-CI

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAnsh MehtaHKHaesook KimVHVincent T. Ho

Discussion

Loading...

Member takes

Overview

Observational study shows prognostic value of HCT-CI in hematopoietic cell transplantation, highlighting comorbidity risks in GVHD prophylaxis.

Key Points

  • To assess the prognostic value of HCT-CI and the impact of HCT-CI on outcomes between PTCY and non-PTCY GVHD prophylaxis.
  • Identified patients with MDS or AML undergoing HCT from 2018 to 2022 at DFCI.
  • Retrieved comorbidity data and clinical outcomes from institutional database validated by chart review.
  • Used Fine and Gray regression analysis and AIC for model assessment.
  • 586 patients included, with 31% using PTCY-based GVHD prophylaxis.
  • Higher HCT-CI score linked to increased NRM (3-year NRM varied across HCT-CI scores).
  • Subset of six comorbidities had similar prognostic power as HCT-CI, especially impacting NRM.

Cite This Study

Mehta et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236defahttps://doi.org/10.1182/blood-2025-4227
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-transplant cyclophosphamide based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants2025
  2. 2Comorbid but transplantable: Favorable outcomes with RIC and ptcy in patients with an HCT-CI score of 3 or higher in the modern era2025
  3. 3Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types2025
  4. 4Post-transplant cyclophosphamide in haploidentical stem cell transplantation: evaluating the impact of transplant conditioning intensity2025
  5. 5Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis2025